Sorry, we do not have enough data to show an influence graph for this author.
- Full text PDF available (0)
- This year (1)
- Last 5 years (2)
- Last 10 years (2)
Journals and Conferences
Introduction Rivaroxaban, an oral factor Xa inhibitor, is approved for therapy of venous thromboembolism. It is unclear whether the standard dose for patients with a body mass index (BMI) > 40 kg/m2… (More)
Direct oral anticoagulants (DOACs) have been introduced within the last years as alternative to vitamin K antagonists (VKAs) as oral anticoagulant drugs (OAC). The mean/median age of the patients… (More)